BDX:NYE-Becton Dickinson and Company (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 238.4

Change

+4.67 (+2.00)%

Market Cap

USD 35.71B

Volume

1.66M

Analyst Target

USD 276.71
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ALC Alcon AG

+0.31 (+0.31%)

USD 49.15B
RMD ResMed Inc

+1.81 (+0.75%)

USD 36.31B
BAX Baxter International Inc

+0.37 (+0.97%)

USD 19.56B
AVTR Avantor Inc

+0.39 (+1.52%)

USD 17.45B
TFX Teleflex Incorporated

-0.07 (-0.03%)

USD 11.58B
ATR AptarGroup Inc

+1.24 (+0.79%)

USD 10.51B
BLCO Bausch + Lomb Corp

+0.02 (+0.11%)

USD 6.72B
STVN Stevanato Group SpA

+0.48 (+2.36%)

USD 5.39B
WRBY Warby Parker Inc

+0.74 (+4.82%)

USD 1.74B
INFU InfuSystems Holdings Inc

+0.60 (+10.07%)

USD 0.13B

ETFs Containing BDX

UMDV:SW iShares US Medical Device.. 6.00 % 0.00 %

N/A

N/A
EQTY Kovitz Core Equity ETF 4.14 % 0.00 %

+0.26 (+0.00%)

USD 1.08B
SPQB:XETRA Global X S&P 500® Quarte.. 3.93 % 0.00 %

-0.11 (0.00%)

USD 0.07B
LS:CA 3.23 % 2.21 %

N/A

N/A
EVOU:PA BNP Paribas Easy ESG Equi.. 2.08 % 0.00 %

+0.75 (+0.00%)

USD 0.01B
VLUD:F BNP Paribas Easy - Equity.. 2.08 % 0.00 %

+0.48 (+0.00%)

USD 0.80M
VLUS:F BNP Paribas Easy - Equity.. 2.08 % 0.00 %

+2.10 (+0.00%)

USD 0.01B
VLUD:XETRA BNP Paribas Easy ESG Equi.. 2.08 % 0.00 %

+0.54 (+0.00%)

USD 0.23M
VLUS:XETRA BNP Paribas Easy ESG Equi.. 2.08 % 0.00 %

+0.75 (+0.00%)

USD 8.86M
VLUU:SW BNP Paribas Easy Equity L.. 2.08 % 0.00 %

N/A

USD 0.55M
IBDK 0.00 % 0.10 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.26 (+0.00%)

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
YLDE ClearBridge Dividend Stra.. 0.00 % 0.59 %

+0.23 (+0.00%)

USD 0.05B
VSL 0.00 % 0.65 %

N/A

N/A
UTRN Vesper U.S. Large Cap Sho.. 0.00 % 0.00 %

+0.24 (+0.00%)

USD 0.02B
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
NSGE:CA NBI Sustainable Global Eq.. 0.00 % 0.00 %

N/A

CAD 0.53B
TACE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.23% 50% F 30% F
Dividend Return 0.78% 60% D- 30% F
Total Return -1.45% 47% F 27% F
Trailing 12 Months  
Capital Gain -7.62% 53% F 19% F
Dividend Return 1.46% 60% D- 23% F
Total Return -6.16% 58% F 18% F
Trailing 5 Years  
Capital Gain -3.60% 55% F 42% F
Dividend Return 6.96% 71% C- 23% F
Total Return 3.36% 45% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain -0.19% 40% F 39% F
Dividend Return 1.17% 35% F 35% F
Total Return 1.36% 64% D 32% F
Risk Return Profile  
Volatility (Standard Deviation) 6.86% 100% F 85% B
Risk Adjusted Return 17.11% 55% F 41% F
Market Capitalization 35.71B 100% F 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.20 27% 11%
Price/Book Ratio 2.68 58% 32%
Price / Cash Flow Ratio 22.60 39% 14%
Price/Free Cash Flow Ratio 19.35 28% 15%
Management Effectiveness  
Return on Equity 5.37% 61% 40%
Return on Invested Capital 4.77% 61% 43%
Return on Assets 3.20% 58% 57%
Debt to Equity Ratio 57.13% 29% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector